TINF2 and hematopoietic and lymphoid cell neoplasm: The risk of solid tumors was highest in individuals with AR/XLR (O:E, 23.97 [95% CI, 10.96-45.50]), whereas O:Es for hematologic malignant neoplasms (including lymphoma) was higher in individuals with AD–non-TINF2 (O:E, 9.41 [95% CI, 4.3-17.86].